Amgen Q3 top line up 2%; EPS up 10%; earnings guidance raised; shares ease 1% after hours

|About: Amgen Inc. (AMGN)|By:, SA News Editor

Amgen (NASDAQ:AMGN) Q3 results ($M): Total Revenues: 5,811 (+1.5%); Product Sales: 5,516 (0%).

Net Income: 2,017 (+8.3%); Non-GAAP Net Income: 2,276 (+9.4%); EPS: 2.68 (+9.8%); Non-GAAP EPS: 3.02 (+11.0%); CF Ops: 2,662 (-8.0%).

Key Product Sales: Enbrel: 1,452 (-0.5%); Neulasta: 1,200 (-5.3%); Aranesp: 531 (+7.7%); Sensipar/Mimpara: 415 (+17.6%); XGEVA: 394 (+4.2%); Prolia: 379 (+18.4%); EPOGEN: 335 (-31.5%); NEUPOGEN: 183 (-35.6%); KYPROLIS: 183 (+33.6%); Vectibix: 164 (+24.2%); Nplate: 151 (+10.2%); Repatha: 40; BLINCYTO: 29.

2016 Guidance: Total Revenues: $22.6B - 22.8B from $22.5B - 22.6B; EPS: $9.94 - 10.11 from $9.55 - 9.90; Non-GAAP EPS: $11.10 - 11.40 (unch).

Consensus view was EPS of $2.79 on revenues of $5.7B.

Shares are off 1% after hours on increased volume.

Subscribe for full text news in your inbox